Oragenics Inc (OGEN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oragenics Inc (OGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10060
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oragenics Inc (Oragenics) focuses on the development and commercialization of novel antibiotics against infectious disease that includes treatments for oral mucositis, healthcare associated infections, obesity and dental disorders. The company develops its product candidates based on various technologies such as Lantibiotics which is a class of antibiotics with a novel mechanism of action active against several multi-drug resistant organisms; live biotherapeutics, which utilizes genetically modified bacteria to treat oral indications and SMaRT Replacement Therapy which is based on the creation of genetically modified strain of bacteria colonizing in the oral cavity and replaces native bacteria that cause tooth decay. Oragenics is headquartered in Tampa, Florida, the US.

Oragenics Inc (OGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oragenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oragenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oragenics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Intrexon Enters into Co-Development Agreement with Oragenics 10
Licensing Agreements 11
Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 11
Equity Offering 13
Oragenics Raises USD13.8 Million Public Offering of Shares and Warrants 13
Oragenics Prices Private Placement of Shares for USD1.8 Million 15
Oragenics Raises USD3.3 Million in Rights Offering of Preferred Shares 16
Oragenics Raises USD6.7 Million in Private Placement of Shares 17
Oragenics Raises USD1.7 Million in Second Tranche of Private Placement of Series A Preferred Stock 18
Oragenics Raises USD1.3 Million in First Tranche of Private Placement of Series A Preferred Stock 19
Oragenics Raises USD4.7 Million in Private Placement of Shares 20
Oragenics Completes Public Offering Of Shares For US$11 Million 22
Oragenics Completes Private Placement Of Shares For US$4 Million 23
Oragenics Completes Private Placement Of Common Stock For US$13 Million 24
Asset Transactions 25
Oragenics Sells Certain Probiotic Business Assets to ProBiora Health 25
Oragenics Inc – Key Competitors 26
Oragenics Inc – Key Employees 27
Oragenics Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Apr 18, 2017: Oragenics Provides First Quarter 2017 Update 29
Product News 30
06/06/2017: Oragenics Presents Development of Novel Lantibiotic Against Clostridium difficile at the ICAAC Conference 30
03/19/2018: Oragenics Announces Peer Reviewed Publication Examining Efficacy of Mutacin 1140 Lantibiotic Variants against Clostridium difficile 31
Clinical Trials 32
Mar 23, 2018: Oragenics Completes Enrollment for the Interim Analysis Cohort in Its Phase 2 Clinical Trial of AG013 for Oral Mucositis 32
Aug 31, 2017: Oragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral Mucositis 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Oragenics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oragenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oragenics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Oragenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Intrexon Enters into Co-Development Agreement with Oragenics 10
Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 11
Oragenics Raises USD13.8 Million Public Offering of Shares and Warrants 13
Oragenics Prices Private Placement of Shares for USD1.8 Million 15
Oragenics Raises USD3.3 Million in Rights Offering of Preferred Shares 16
Oragenics Raises USD6.7 Million in Private Placement of Shares 17
Oragenics Raises USD1.7 Million in Second Tranche of Private Placement of Series A Preferred Stock 18
Oragenics Raises USD1.3 Million in First Tranche of Private Placement of Series A Preferred Stock 19
Oragenics Raises USD4.7 Million in Private Placement of Shares 20
Oragenics Completes Public Offering Of Shares For US$11 Million 22
Oragenics Completes Private Placement Of Shares For US$4 Million 23
Oragenics Completes Private Placement Of Common Stock For US$13 Million 24
Oragenics Sells Certain Probiotic Business Assets to ProBiora Health 25
Oragenics Inc, Key Competitors 26
Oragenics Inc, Key Employees 27
Oragenics Inc, Other Locations 28

List of Figures
Oragenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oragenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Oragenics Inc (OGEN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • 4D Molecular Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary 4D Molecular Therapeutics Inc (4D Molecular Therapeutics) focuses on the discovery and development of targeted and proprietary AAV gene therapy vectors and therapeutic products. The company developed a discovery platform, Directed Vector Evolution, which empowers to create customized gene de …
  • The Walsh Group:企業の戦略的SWOT分析
    The Walsh Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Bahamas Petroleum Company Plc (BPC):石油・ガス:M&Aディール及び事業提携情報
    Summary Bahamas Petroleum Company Plc (Bahamas Petroleum), formerly BPC plc, is an oil and gas exploration company. The company invests in an offshore oil exploration programme in licence areas in the territorial waters and maritime Exclusive Economic Zone of The Bahamas. It holds interests in five …
  • Garden Fresh Restaurants, LLC:企業の戦略・SWOT・財務分析
    Garden Fresh Restaurants, LLC - Strategy, SWOT and Corporate Finance Report Summary Garden Fresh Restaurants, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • DB HiTek Co Ltd (000990):企業の財務・戦略的SWOT分析
    DB HiTek Co Ltd (000990) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • GeNeuro SA (GNRO):企業の財務・戦略的SWOT分析
    Summary GeNeuro SA (GeNeuro) operates as a clinical stage pharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. The company provides treatments against inflammatory and degenerative disorders associated with endogenous retroviruses. GeNeuro develo …
  • Geberit Ag
    Geberit Ag - Strategy, SWOT and Corporate Finance Report Summary Geberit Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • SalvaRx Group plc (SALV):企業の財務・戦略的SWOT分析
    Summary SalvaRx Group Plc (SalvaRx), formerly 3Legs Resources plc, is a drug development company that offers acquiring and operating drug development programmes in immuno-oncology. The company offers immune oncology. It invests in novel cancer immune-therapies. SalvaRx provides development of a pipe …
  • Grupo Aeroportuario del Centro Norte SAB de CV:企業の戦略・SWOT・財務情報
    Grupo Aeroportuario del Centro Norte SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Grupo Aeroportuario del Centro Norte SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Ingram Entertainment Inc.:戦略・SWOT・企業財務分析
    Ingram Entertainment Inc. - Strategy, SWOT and Corporate Finance Report Summary Ingram Entertainment Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Franklin Resources, Inc.:企業のM&A・事業提携・投資動向
    Franklin Resources, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Franklin Resources, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Basin Electric Power Cooperative
    Basin Electric Power Cooperative - Strategy, SWOT and Corporate Finance Report Summary Basin Electric Power Cooperative - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Creekside Springs, LLC:企業の戦略・SWOT・財務情報
    Creekside Springs, LLC - Strategy, SWOT and Corporate Finance Report Summary Creekside Springs, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Mendor Oy-製薬・医療分野:企業M&A・提携分析
    Summary Mendor Oy (Mendor) is a medical equipment company that designs, develops and markets advanced diabetes management products. The company’s products include portable blood glucose meter and web-based software application for the daily management of diabetes. It offers blood glucose meter mendo …
  • Intersurgical Ltd.:企業の戦略的SWOT分析
    Intersurgical Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Spinal Elements Inc:医療機器:M&Aディール及び事業提携情報
    Summary Spinal Elements Inc (Spinal Elements), formerly Quantum Orthopedics Inc, a subsidiary of Spinal Elements, is a medical device manufacturing company that manufactures spinal implants and instruments. The company provides products such as cervical implant systems, anterior cervical plate syste …
  • Slovnaft AS (1SLN01AE):企業の財務・戦略的SWOT分析
    Slovnaft AS (1SLN01AE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Lee’s Pharmaceutical Holdings Ltd (950):製薬・医療:M&Aディール及び事業提携情報
    Summary Lee's Pharmaceutical Holdings Ltd (Lee's Pharmaceutical) is a biopharmaceutical company that offers development of novel therapies and contract research services. The company provides products in the treatment of disease areas such as urology, cardiovascular oncology, dermatology, hematology …
  • Regis Corporation (RGS):企業の財務・戦略的SWOT分析
    Regis Corporation (RGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Sequella Inc:医療機器:M&Aディール及び事業提携情報
    Summary Sequella Inc (Sequella) is a clinical-stage pharma company that develops antibiotics to address drug resistant bacterial, fungal, and parasitic infections. The company’s pipeline products comprise SQ109, Sutezolid, SQ641 and SQ609; and a novel rapid antibiotic susceptibility test, B-SMART. S …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆